3-(1,3,4-氧杂二唑-2-基)苯酚 | 5378-29-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 中文名称: 3-(1,3,4-氧杂二唑-2-基)苯酚
• 英文名称: 2-(3-hydroxyphenyl)-1,3,4-oxadiazole
• 英文别名: 3-(1,3,4-oxadiazol-2-yl)phenol；3-[1,3,4]oxadiazol-2-yl-phenol；3-([1,3,4]-Oxadiazol-2-yl)phenol；3-(1,3,4-oxadiazol-2-yl)-phenol；2-<3-Hydroxy-phenyl>-1,3,4-oxdiazol
• CAS: 5378-29-0
• 化学式: C₈H₆N₂O₂
• mdl: MFCD06643238
• 分子量: 162.148
• InChiKey: CSMNFUDFDBVTHP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  59.2
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-(1,3,4-Oxadiazol-2-yl)phenol
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-(1,3,4-Oxadiazol-2-yl)phenol
CAS number: 5378-29-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H6N2O2
Molecular weight: 162.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-(1,3,4-氧杂二唑-2-基)苯酚 在 2-吡啶甲酸 、 potassium phosphate 、 copper(l) iodide 、 四丁基溴化铵 作用下， 以 溶剂黄146 、 二甲基亚砜 为溶剂， 反应 240.0h， 生成
  参考文献：
  名称：

  一类四齿环金属铂(II)配合物磷光发光材料

  摘要：

  本发明公开了一类如式(I)所示的四齿环金属铂(II)磷光发光材料：其中，五元杂芳香基团Ar为所述的Ar选自下列之一：2H‑1,2,3‑三唑其中，X1＝N,X2＝N,X3＝CH)；1H‑1,2,3‑三唑其中，X1＝CH,X2＝N,X3＝N；1,3,4‑噁二唑其中，X1＝O,X2＝C,X3＝N；噁唑其中，X1＝O,X2＝C,X3＝CH或噻唑其中，X1＝S,X2＝C,X3＝CH。本发明所述的四齿环金属铂(II)磷光发光材料中的一种或两种及以上在作为有机发光器件的发光层中的应用。本发明所述的四齿环金属铂(II)磷光发光材料分子刚性强，可以有效减少由于分子振动所消耗的能量，磷光量子效率高，化学稳定性和热稳定性好。

  公开号：

  CN107266505B
• 作为产物：
  描述：

  3-苯甲氧基苯甲酰氯 在 palladium 10% on activated carbon 、 甲酸铵 、 氯化铵 、 一水合肼 作用下， 以 甲醇 、 乙醇 为溶剂， 反应 5.0h， 生成 3-(1,3,4-氧杂二唑-2-基)苯酚
  参考文献：
  名称：

  用1 H -1,2,3-三唑取代末端酰胺：鉴定出意想不到的强效抗菌剂

  摘要：

  3-甲氧基苯甲酰胺（3-MBA）衍生物已被确定为针对细菌细胞分裂蛋白FtsZ的新型有效抗菌剂。作为酰胺基团的等排体之一，1,2,3-三唑可以模拟酰胺的拓扑和电子特征，这在药物开发中已引起越来越多的关注。基于这些考虑，我们通过用三唑等位取代末端酰胺，制备了一系列含有1 H -1,2,3-三唑的3-MBA类似物，从而提高了抗菌活性。这项研究证明了发展1 H -1,2,3-三唑基作为末端酰胺模拟元件的可能性，该模拟元件能够保持和调节酰胺相关的生物活性。令人惊讶的是，这些新的1观察到含有H -1,2,3-三唑的类似物，这可能为开发抗菌剂打开新的机会。

  DOI：

  10.1016/j.bmcl.2018.02.001

文献信息

• Compounds enhancing antitumor activity of other cytotoxic agents
  申请人：Pfizer Inc

  公开号：US06130217A1

  公开（公告）日：2000-10-10

  This invention relates to certain heterocyclic compounds and their pharmaceutically acceptable salts, which are useful for sensitizing multidrug-resistant tumor cells to anticancer agents and multidrug resistant forms of malaria, tuberculosis, leishmania and amoebic dysentery to chemotherapeutants. The compounds and their pharmaceutically acceptable salts are also inhibitors of the active drug transport capability of P-glycoprotein which is encoded by the human MDR1 gene, as well as of certain other related ATP-binding-cassette transporters from eukaryotic and prokaryotic organisms (e.g., pfmdr from Plasmodium falciprum, and murine mdr1 and mdr3 gene products).

  这项发明涉及某些杂环化合物及其药用可接受的盐，这些化合物对于使多药耐药肿瘤细胞对抗癌药物和多药耐药形式的疟疾、结核病、利什曼病和阿米巴痢疾对化疗药物具有敏感性是有用的。这些化合物及其药用可接受的盐还是人类MDR1基因编码的P-糖蛋白的活性药物转运能力的抑制剂，以及来自真核和原核生物（例如，来自疟原虫的pfmdr，以及小鼠mdr1和mdr3基因产物）的某些其他相关的ATP结合盒转运蛋白的抑制剂。
• 含有四齿配体的四价金属铂配合物、制备方 法、应用及器件
  申请人：浙江工业大学

  公开号：CN109608506B

  公开（公告）日：2021-08-06

  本发明涉及有机发光材料技术领域，其提供了一种含有四齿配体的四价金属铂配合物磷光发光材料。所述含有四齿配体的四价金属铂配合物具有通式(I)所示的结构。同时，本发明还提供所述含有四齿配体的四价金属铂配合物的制备方法，所述含有四齿配体的四价金属铂配合物在电致发光器件中的应用及一种器件，所述器件包含所述含有四齿配体的四价金属铂配合物。本发明所提供的所述含有四齿配体的四价金属铂配合物通过调节围绕金属中心的配体的结构以及调控配体上取代基的结构来调控四齿环金属铂配合物的光物理学性质，具有稳定性高的优点；其在OLED显示和照明等诸多领域具有广阔的应用前景。
• [EN] ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE<br/>[FR] ISOXAZOLINES EN TANT QU'INHIBITEURS DE L'HYDROLASE DES AMIDES D'ACIDES GRAS
  申请人：INFINITY PHARMACEUTICALS INC

  公开号：WO2010135360A1

  公开（公告）日：2010-11-25

  The present invention provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, Ra, Rb, Rc, and Rd are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient. The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof.

  本发明提供了式(I)的异噁唑啉FAAH抑制剂或其药用可接受形式，其中G、Ra、Rb、Rc和Rd中的每一个如本文所定义。本发明还提供了包括式(I)化合物或其药用可接受形式以及药用可接受赋形剂的药物组合物。本发明还提供了治疗FAAH介导疾病的方法，包括向需要的受试者施用式(I)化合物或其药用可接受形式的治疗有效量。
• [EN] SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT<br/>[FR] COMPOSÉS CYCLOPROPYLIQUES SUBSTITUÉS, COMPOSITIONS CONTENANT DE TELS COMPOSÉS ET PROCÉDÉS DE TRAITEMENT
  申请人：MERCK & CO INC

  公开号：WO2009129036A1

  公开（公告）日：2009-10-22

  Substituted cyclopropyl compounds of formula (I) are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. Pharmaceutically acceptable salts and solvates are included as well. The compounds are useful as agonists of the g-protein coupled receptor GPR-119.

  公式（I）的取代环丙基化合物被披露为治疗或预防2型糖尿病及类似疾病的有效药物。还包括药用可接受的盐和溶剂化合物。这些化合物可作为G蛋白偶联受体GPR-119的激动剂。
• Phenylpiperazine derivatives of hetarylphenols and hetarylanilines,
  申请人：BASF Aktiengesellschaft

  公开号：US04619929A1

  公开（公告）日：1986-10-28

  Novel phenylpiperazinylpropane and -butane derivatives of hetarylphenols and hetarylanilines of the formula ##STR1## where R.sup.1 is hydrogen or alkyl of 1 to 4 carbon atoms, R.sup.2 is hydrogen, halogen, alkyl of 1 to 4 carbon atoms or alkoxy where alkyl is of 1 to 3 carbon atoms, the phenyl ring can be monosubstituted or disubstituted by R.sup.2, X is oxygen or an NH group, and the heterocyclic structure Het. is 1,3,4-oxadiazolyl, triazolyl, imidazolyl or pyrazolyl, and their physiologically tolerated addition salts with acids, processes for their preparation, and pharmaceutical formulations which contain these compounds and exhibit predominantly sedative, neuroleptic and hypotensive properties.

  新型苯基哌嗪基丙烷和丁烷衍生物，其为杂环酚和杂环苯胺的化合物，化学式为##STR1##其中R.sup.1为氢或1至4个碳原子的烷基，R.sup.2为氢、卤素、1至4个碳原子的烷基或烷氧基，其中烷基为1至3个碳原子，苯环可以被R.sup.2单取代或双取代，X为氧或NH基团，杂环结构Het.为1,3,4-噁二唑基、三唑基、咪唑基或吡唑基，以及它们与酸形成的生理耐受性盐，其制备方法，以及含有这些化合物并表现出主要镇静、神经阻滞和降压特性的药物配方。